Laura Clague Net Worth

The estimated Net Worth of Laura Clague is at least $2.45 Milione dollars as of 27 April 2022. Ms. Clague owns over 50,000 units of Retrophin stock worth over $19,902 and over the last 13 years she sold RTRX stock worth over $1,130,445. In addition, she makes $1,303,580 as Chief Financial Officer e Senior Vice President at Retrophin.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Clague RTRX stock SEC Form 4 insiders trading

Laura has made over 15 trades of the Retrophin stock since 2013, according to the Form 4 filled with the SEC. Most recently she exercised 50,000 units of RTRX stock worth $66,500 on 27 April 2022.

The largest trade she's ever made was exercising 50,000 units of Retrophin stock on 27 April 2022 worth over $66,500. On average, Laura trades about 4,001 units every 73 days since 2012. As of 27 April 2022 she still owns at least 284,311 units of Retrophin stock.

You can see the complete history of Ms. Clague stock trades at the bottom of the page.

Laura Clague biography

Laura M. Clague, CPA is the Senior Vice President and Chief Financial Officer of the Company. Ms. Clague previously served as the Chief Financial Officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., a wholly owned subsidiary of Bristol-Myers Squibb. Prior to the acquisition by Bristol-Myers Squibb in 2012, Ms. Clague was the Vice President, Corporate Controller and Chief Accounting Officer of Amylin for 10 years, and during this time also served as the Chief Financial Officer of the Amylin/Lilly Collaboration. From 1988 to 1999, Ms. Clague was the director of finance and accounting operations for Sony Electronics, Inc. From 1985 to 1988, Ms. Clague served as internal audit supervisor at Cubic Corporation. From 1982 to 1985, Ms. Clague held various audit positions at KPMG. Ms. Clague also serves on the Board of Directors of Genasys Inc. (formerly LRAD Corporation) where she chairs the Audit Committee and is on the Nominating and Governance Committee and she is also a board member of Fluidigm Corporation where she serves on the Audit Committee. Ms. Clague is a certified public accountant in the State of California, and has a B.S. in Business Administration from Menlo College.

What is the salary of Laura Clague?

As the Chief Financial Officer e Senior Vice President of Retrophin, the total compensation of Laura Clague at Retrophin is $1,303,580. There are 5 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of $9,679,320.

How old is Laura Clague?

Laura Clague is 61, she's been the Chief Financial Officer e Senior Vice President of Retrophin since 2014. There are 3 older and 11 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.

What's Laura Clague's mailing address?

Laura's mailing address filed with the SEC is 16262 WEST BERNARDO ROAD, , SAN DIEGO, CA, 92127.

Insiders trading at Retrophin

Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer e Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.

What does Retrophin do?

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Complete history of Ms. Clague stock trades at Standard BioTools Inc, Retrophin e Genasys Inc

Retrophin executives and stock owners

Retrophin executives and other stock owners filed with the SEC include:

• Eric Dube,
  President, Chief Executive Officer, Director
• Elizabeth Reed,
  Senior Vice President, General Counsel and Corporate Secretary
• Noah Rosenberg,
  Chief Medical Officer
• Peter Heerma,
  Chief Commercial Officer
• William Rote,
  Senior Vice President and Head of Research and Development
• Laura Clague,
  Chief Financial Officer, Senior Vice President
• Stephen Aselage,
  Director
• Sandra Poole,
  Independent Director
• Gary Lyons,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• Jeffrey Meckler,
  Independent Director
• John Orwin,
  Independent Director
• Roy Baynes,
  Independent Director
• Ron Squarer,
  Independent Director
• Suzanne Bruhn,
  Independent Director
• Neil F. Mc Farlane,
  Chief Operating Officer
• Jensen Margaret E Valeur,
  General Counsel
• John W Kozarich,
  Director
• Alvin Shih,
  EVP of Research & Development
• Cornelius E Golding,
  Director
• Steve Aselage,
  Director
• Martin Shkreli,
  Chief Executive Officer
• Steven Gary Richardson,
  Director
• Horacio Plotkin,
  Chief Medical Officer
• Jeffrey Paley,
  Director
• Marc L Panoff,
  Chief Financial Officer